TOLL-LIKE RECEPTOR-4 (TLR-4) is a type I transmembrane glycoprotein and is mainly expressed on the cells of the innate immune system. TLR-4 can be found in a wide spectrum of cell types, including endothelial cells (ECs) (1, 9, 18) , monocytes (9, 32) , neutrophils (24) , and platelets (2) . As its primary ligand, lipopolysaccharide (LPS) can activate the innate immune system via TLR-4, leading to gene transcription and the release of proinflammatory cytokines. TLR-4 has been shown to be involved in cardiovascular diseases. TLR-4 expression is markedly enhanced in human atherosclerotic plaques and colocalizes with ECs and macrophages (9) . TLR-4 has also been implicated in the regulation of thrombosis formation (9, 16, 33) . A previous in vivo study (9) has demonstrated that platelet-derived TLR-4 is sufficient to promote microvascular thrombosis in endotoxemia, independent of systemic increases in TNF-␣ or IL-1␤; however, the role of TLR-4 in the interplay between platelets and other cell types, such as ECs, remains unclear. In vivo, TLR-4-deficient (TLR-4 Ϫ/Ϫ ) mice are protected from the microvascular thrombotic response to LPS, suggesting a prothrombotic role for TLR-4 (33) . Interestingly, platelets from TLR-4 Ϫ/Ϫ mice showed no significant difference in aggregation when treated with platelet agonists, such as ADP or collagen (33) . This could be explained by other mechanisms, such as the contribution of TLR-4 from the vasculature to thrombus formation. Thus, vascular wall-derived TLR-4 could play a role in the pathophysiology of arterial thrombosis.
Tissue factor (TF), a critical initiator of blood clotting, is present in atherosclerotic plaque and triggers thrombosis after plaque rupture (22) . Several studies (3, 27) have shown that LPS induces TF expression in monocytes and ECs. Based on these endotoxin-triggered effects, TLR-4 has been postulated to play a role in the induction of TF expression as well as in thrombosis formation. Recently, it has been shown that TLR-4 mediates TF expression by different mechanisms in THP-1 cells (29) . TLR-4, present in atherosclerotic plaque because of deposition from plasma (2, 24, 32) and local synthesis from vascular cells (1, 9, 18) , induces TF expression in ECs (34) and macrophages (9) . Therefore, TLR-4-induced TF expression by ECs may promote thrombosis after endothelial disruption. In the present study, we hypothesized that vascular wall-derived TLR-4 has a role in the regulation of arterial thrombosis and that TLR-4 modulates TF expression in ECs.
MATERIALS AND METHODS

Animals
. Male mice at 12-24 wk old were used. C57BL/10J [wild-type (WT) control] and TLR-4 Ϫ/Ϫ mice were purchased from the Model Animal Research Center of Nanjing University (Nanjiang, China). Mice were maintained on a 12:12-h light-dark cycle. All protocols for animal use were reviewed and approved by the Animal Care Committee of Luzhou Medical College in accordance with Institutional Animal Care and Use Committee guidelines.
Carotid artery thrombosis model. FeCl 3 vascular injury to the midportion of the common carotid artery was performed on pentobarbital-anesthetized mice as previously described (10) . Briefly, mice were anesthetized, the left carotid artery was dissected, and filter paper soaked in FeCl 3 solution (3.5%) was placed on the carotid artery. After 3 min, the filter paper was removed, the carotid artery was washed with PBS, and the flow was recorded by a color LaserDoppler Image scanner (Moor LDI, Moor Instruments) as previously described (15) . Flow was monitored continuously from the onset of injury until stable occlusion occurred (defined as no flow for Ն10 min) or for 60 min if occlusion did not occur. Occlusion time was defined as the interval between the initiation of vascular injury and the onset of stable occlusion (5, 10) . To further determine the influence of endotoxemia on arterial thrombosis, mice were injected intraperitoneally with either sterile saline or endotoxin (Sigma) at 5 mg/kg in 500 l sterile saline 4 h before FeCl 3 injury, as previously described (31, 33) . Injured and contralateral uninjured carotid segments were isolated for analysis of quantitative real-time PCR and immunohistochemistry.
Leukocyte-depleted platelet preparation and injection. Mouse blood was collected from the inferior vena cava, and platelets were prepared as previously described (25) . Platelets were resuspended in Beads buffer (0.8% NaCl, 0.02% KCl, 0.144% Na 2HPO4, 0.024% K 2HPO4, 0.5% BSA, and 2 mM EDTA). Mouse CD45 MicroBeads reagent (Miltenyi Biotec) was added, and the suspension was incubated at room temperature for 45 min with gentle mixing. Leukocytedepleted platelets were collected using magnetic separation columns (Miltenyi Biotec), and the final products were obtained by RNA extraction and RT-PCR.
Leukocyte-depleted platelets (ϳ3 ϫ 10 9 ) obtained from donor mice in resuspension buffer were injected into a single recipient via the tail vein. Control animals were injected with resuspension buffer. One hour after the reinfusion of platelets, blood was once again collected and analyzed by the blood counter. If the new circulating platelet count successfully rose to levels of 3-5 ϫ 10 9 , the artery injury was subsequently performed with FeCl 3.
Platelet depletion. To deplete endogenous platelets, mice were induced by intraperitoneal injections every 3 days with 2.5 g/g mouse of platelet-depleting antibody (polyclonal anti-mouse GPIb␣ rat IgG, Emfret Analytics). Control mice were injected with nonimmune rat polyclonal IgG (Emfret Analytics). Platelets were evaluated by blood count. The intraperitoneal injection of the depleting antibody resulted in Ն95% reduction in circulating platelets at 12 h postinjection in all mice.
Primary culture of aortic ECs. Primary murine aortic ECs were isolated as previously described (21) with modifications. Briefly, freshly isolated aortas were digested with 1 mg/ml collagenase type I (Worthington, Lakewood, NJ) and filtered through 70-m nylon filters. ECs were then purified with rat anti-mouse CD31-coupled magnetic beads (Miltenyi Biotec) and a magnetic separator. Primary ECs were cultured in DMEM containing 10% FCS, and purity was Ͼ95%, as examined by immunostai uptake of Dil-Ac-LDL (Biomedical Technologies, Stoughton, MA) and flow cytometric evidence of anti-CD31 (Invitrogen). Cells passaged two to seven times were used in this study.
Measurement of TF activity. TF activity was performed as previously described (38) . In brief, ECs were lysed with RIPA buffer (Sigma). Equal amounts of cell lysates were added to 96-well microtiter plates containing human factor VIIa (3 nmol/l), human factor X (100 nmol/l, Hematologic Technologies), 8.3 mmol/l CaCl2, and Spectrozyme fXa (0.33 mmol/l, American Diagnostica). In some sets, ECs were treated with 100 ng/ml LPS (Sigma) in the absence or presence of 10 g/ml anti-TLR-4 antibody (R&D Systems) for 24 h (18). Carotid arteries were homogenized in 50 mmol/l Tris·HCl (pH 8.0) for the TF activity assay. The protein concentration of centrifuged extracts was determined with BCA reagent (Pierce). TF activity was measured using an Actichrome TF activity assay (American Diagnostica).
Quantitative real-time PCR. Total RNA was extracted from carotid arteries using TRIzol (Invitrogen). RNA was pretreated with deoxyribonuclease I (Invitrogen-Life Technologies), and SuperScript (Invitrogen-Life Technologies) was used to synthesize cDNA according to the manufacturer's recommended conditions. Real-time quantitative PCR analysis was performed using an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The primer sequences used for murine TF were as follows: forward 5=-GAAGGATGTGACCTGGGCC-3= and reverse 5=-TACCATTCT-TTCTGACTAA-3= (38) . Each sample was analyzed in duplicate with 18S rRNA used as an internal control. After amplification, the relative differences in the amounts of RNA were calculated based on the 2 Ϫ⌬⌬CT method, where CT is threshold cycle.
Immunoblot analysis. Cells were lysed by RIPA buffer (Sigma). Equal amounts of protein were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes by electroblotting.
After being blocked, membranes were incubated with rabbit antimouse TLR-4 (Abcam, Cambridge, MA) and GAPDH (Cell Signaling Technology).
Immunohistochemistry. Carotid artery cross-sections (5 m) were mounted on glass slides. Slides were blocked and incubated with rabbit IgG raised against mouse TF (American Diagnostica). Negative controls were incubated without primary antibody. Secondary antibody was biotinylated goat IgG raised against rabbit IgG (Santa Cruz Biotechnology). Immunostaining conditions and imaging settings were identical for all directly compared cells and tissues. All images shown in figures are representative of at least triplicate experiments.
We performed volumetric measurements for thrombus on digitizing images using Olympus Microsuite software (Olympus Soft Imaging Solutions, Lakewood, CO). We calculated carotid artery thrombus volumes from each cross-section and compared them between WT and TLR-4 Ϫ/Ϫ mice. Statistical analysis. Data are expressed as means Ϯ SE of at least triplicate experiments. Experimental groups were compared using a two-tailed Student's t-test or one-way ANOVA.
RESULTS
TLR-4
Ϫ/Ϫ mice are less susceptible to thrombosis in vivo. We examined age-and sex-matched WT and TLR-4 Ϫ/Ϫ mice using a carotid artery injury model. 
Contribution of platelet and vascular cell TLR-4 to thrombus formation in vivo.
Based on a previous study (33) and our data, compared with WT mice, platelets isolated from TLR-4 Ϫ/Ϫ mice were not significantly different in the aggregation response to collagen and thrombin (data not shown). To further address the contribution of platelet-derived TLR-4, we used a platelet depletion model to examine thrombus formation in vivo in different groups. Carotid artery thrombosis was induced with FeCl 3 . Platelet counts were equivalent in whole blood of the donor, and all recipients were under thrombocytopenic conditions before manipulation ( Fig. 2A) . Plasma-rich platelets prepared by standard density centrifugation are contaminated with leukocytes, and thus leukocyte-derived cytokines may influence the effect of platelets. Mouse platelets were therefore isolated and purified by depleting leukocytes before injection to the recipient animal. Furthermore, successful platelet depletion and reinfusion were verified in recipient WT and TLR-4 Ϫ/Ϫ mice (Fig. 2B) . We evaluated the occlusion time in the four groups of platelet depletion/reinfusion mice in a carotid artery injury model. In the platelet-depleted WT mouse group, we found that either WT or TLR-4 Ϫ/Ϫ -derived platelet reinfusion did not change the mean occlusion time compared with the WT mouse group. Similarly, in the platelet-depleted TLR-4 Ϫ/Ϫ mouse group, there was also no significant difference by either WT or TLR-4 Ϫ/Ϫ -derived platelet reinfusion compared with the TLR-4 Ϫ/Ϫ mouse group (Fig. 2C) . This indicates that platelet be- Ϫ/Ϫ mice compared with WT mice (Fig.   3B ). In contrast, TF expression was barely detected in vascular smooth muscle cells (VSMCs) of medial arteries in both WT and TLR-4 Ϫ/Ϫ mice. In control carotid arteries, intense TF staining was only present in the adventitia. TF activity was significantly less in carotid artery extracts of TLR-4 Ϫ/Ϫ mice compared with WT mice (Fig. 3C) . Furthermore, we examined TF activity in carotid arteries injured by FeCl 3 in four groups of platelet depletion/reinfusion mice. In the platelet-depleted WT mouse group, we found that the WT or TLR-4 Ϫ/Ϫ -derived mice. B: platelet depletion was achieved by injection of anti-mouse GPIb␣ rat IgG. Platelet counts were successfully reduced by injection of anti-mouse GPIb␣ rat IgG and successfully restored after reinfusion of platelets from a donor mouse to thrombocytopenic mice (n ϭ 4). *P Ͻ 0.05 vs. depleted WT mice; **P Ͻ 0.05 vs. depleted TLR-4 Ϫ/Ϫ mice. C: mean times to occlusion of carotid arteries were measured from the four groups of mice generated by the platelet depletion/reinfusion model. WT and TLR-4 Ϫ/Ϫ mice were used as normal controls without platelet depletion/reinfusion. n ϭ 4 mice/group. *P Ͻ 0.05 vs. WT mice.
platelet reinfusion did not significantly change TF activity compared with the WT mouse group. Similarly, in the plateletdepleted TLR-4 Ϫ/Ϫ mouse group, there was also no significant difference in the WT or TLR-4 Ϫ/Ϫ -derived platelet reinfusion compared with the TLR-4 Ϫ/Ϫ mouse group (Fig. 3D) .
Role of TLR-4 in the induction of TF expression and activity by LPS. To examine the impact of TLR-4 on EC TF expression, we cultured ECs from WT and TLR-4
Ϫ/Ϫ mice. TLR-4 was expressed in WT ECs and platelets (Fig. 4A) . Cell surface TF activity was significantly greater for WT ECs than for TLR-4 Ϫ/Ϫ ECs (Fig. 4B) . To further characterize the role of TLR-4 in TF expression, ECs were treated with LPS for 24 h. In WT ECs, LPS increased TF mRNA but no effect in TLR-4 Ϫ/Ϫ ECs (Fig. 4C) . To further determine whether TLR-4 activation triggered TF activity, WT ECs were grown in the presence of anti-TLR-4 antibody. The results showed that 10 g/ml TLR-4 antibody effectively antagonized the induction of TF activity by LPS from WT ECs (Fig. 4D) . To determine the influence of LPS on arterial thrombosis, mice were injected intraperitoneally with either saline or LPS. The average occlusion time in WT mice treated with LPS (91.7 Ϯ 16.2 s, n ϭ6) was significantly shorter than that of WT mice treated with saline (189.3 Ϯ 21.1 s, n ϭ 6, P Ͻ 0.05); however, there were no differences in occlusion time between WT and TLR-4 Ϫ/Ϫ mice exposed to LPS or saline (298.7 Ϯ 27.3 vs. 306.7 Ϯ 26.1 s, n ϭ 6, P Ͼ 0.05; Fig. 4E ). These results suggest that LPS may activate the TF expression and activity required for TLR-4 signaling.
DISCUSSION
We examined the susceptibility of TLR-4 Ϫ/Ϫ mice to arterial thrombosis and demonstrated that TLR-4 deficiency attenuated arterial thrombosis in a FeCl 3 injury model. We report that TLR-4 is required for the upregulation of expression and activity of TF in vascular cells. These results suggest that EC-derived TF expression through TLR-4 signaling is presumably associated with arterial thrombosis.
TLR-4 is known for its role in other disorders of the circulatory system. Previous studies have shown that TLR-4 is strongly associated with thrombosis and coagulation (9, 29, 33) and have suggested that platelet-derived TLR-4 was sufficient Ϫ/Ϫ (n ϭ 4) mice. B: immunohistochemistry of carotid arteries using anti-TF antibody. n ϭ 4. Magnification: ϫ600. C: TF activity of carotid artery extracts (n ϭ 4/group). *P Ͻ 0.05. D: TF activity of carotid artery extracts was performed from the four groups of mice generated by the platelet depletion/reinfusion model. WT and TLR-4 Ϫ/Ϫ mice were used as normal controls without platelet depletion/reinfusion. n ϭ 4 mice/group. *P Ͻ 0.05 vs. WT mice.
to mediate the enhanced microvascular thrombosis in response to LPS (33) . Interestingly, in the present study, we found that platelet TLR-4 expression does not influence platelet aggregation without LPS. It is generally accepted that the initial thrombus formation after nonvascular injury is triggered by prothrombotic factors present in hematopoietic sources, such as platelets or leukocytes. However, there seems to be a discrepancy between this platelet behavior and the observed prothrombotic effect, leading to the hypothesis that vessel wall-derived TLR-4 plays a significant role in thrombus formation, especially in ECs and smooth muscle cells.
To further study thrombosis in mice with selective ablations of TLR-4 in hematopoietic or nonhematopoietic compartments, we created chimeric mice for the depletion/reinfusion of platelets, exhibiting either platelet TLR-4 only, vascular cell TLR-4 only, both platelet and vascular cell TLR-4, or neither. As previously described, compared with bone marrow transplantation, this model avoids the inherent problem of thrombus instability after irradiation (26, 30) . We found that the mean occlusion time using platelets from WT mice was similar to platelets from TLR-4 Ϫ/Ϫ chimeric mice. Our results revealed the key role of TLR-4 from the vascular wall in arterial thrombosis formation and strongly suggest a contribution of the nonhematopoietic compartment. Because leukocytes play a crucial role in the initiation and propagation of thrombosis, we used leukocyte-depleted platelets in the reinfusion model, thereby eliminating the involvement of leukocytes in the formation of thrombi.
A recent study (33) has found that platelet TLR-4 does not have an effect on platelet aggregation. However, the authors showed that TLR-4 was associated with microvascular thrombosis in response to LPS. The mechanisms involved in the prothrombotic state in the microvasculature remain to be determined. LPS promotes platelet thrombus formation indepen- dent of neutrophils and without the enhancement of platelet aggregation via a TLR-4-dependent mechanism (31) . Under normal conditions, ECs do not express TF. However, a variety of stimuli, including LPS, induce TF expression in ECs in vitro (18, 20) . Therefore, it is likely that TLR-4 mediates a prothrombotic phenotype via the EC. Indeed, TLR-4 also contributes to the activation of ECs during inflammation (11, 18) . Thus, we examined TF as a possible mechanism of the TLR-4 pathway in arterial thrombosis. Arterial thrombosis is initiated by the interaction of TF in the vascular wall with platelets and coagulation factors in the circulating blood. The source of TF in thrombosis is still under debate (4, 11, 13, 36) . The FeCl 3 injury model causes EC denudation but does not expose the inner layers and would be expected to generate and introduce TF into the circulation, including the endothelium, vascular smooth muscle, circulating cells, and microparticles (5, 6, 8, 30, 36) . Although the relative contributions of vessel wall-bound versus circulating TF to thrombosis remain to be determined, it is clear that TF plays a critical role in mediating arterial thrombosis by FeCl 3 .
In the present study, we found that TF is upregulated in the endothelium in FeCl 3 -induced arterial thrombosis. We isolated ECs from the mouse aortic artery and used LPS as a procoagulant stimulus. We found that ECs isolated from TLR-4 Ϫ/Ϫ mice had significantly lower TF activity compared with WT ECs. Interestingly, we found that the induction of TF activity by LPS from WT ECs was blocked by TLR-4 antibody. These results suggest that LPS may activate the TF activity required for TLR-4 signaling in ECs. However, it is important to note that TF is also markedly induced in medial VSMCs and associated with arterial thrombosis by FeCl 3 (35) . Notably, VSMCs derived from injured arteries failed to detect TF expression. This may support the crucial role of TLR-4 in the induction of TF in ECs. The present study was performed on intrinsically normal arteries, which express low levels of TF, whereas human atherosclerotic plaques contain TF-enriched macrophages, VSMCs, and ECs. It is still possible that some pathological environments, such as atherosclerosis and inflammation, are the major determinants for TLR-4 in VSMCs. The nature of the cell type specificity for TLR-4 expression should further be addressed. This study suggests that vascular-derived TF plays a key role in mediating arterial thrombosis. The EC TLR-4 Ϫ/Ϫ mouse should be valuable in further determining the role of EC-derived TF in mediating arterial thrombosis and other pathological processes.
LPS exhibits prothrombotic effect through activation of ECs and increased platelet reactivity since LPS was shown to stimulate increased expression of TF, endothelial P-selectin, and plasminogen activator inhibitor-1 (7, 14, 17) . LPS acts as a ligand for TLR-4 and activates the signaling pathways through NF-B and p38 MAPK, leading to the subsequent induction of various proinflammatory cytokines (37) . Previous studies have demonstrated that the effects of LPS in experimental models of thrombosis are likely to reflect the initial innate immune response. Here, we showed that LPS accelerates arterial thrombosis formation in WT mice but not TLR-4 Ϫ/Ϫ mice in the current models. Furthermore, we found that TLR-4 signaling is required to activate TF activity in cultured ECs by LPS stimulation.
Perspectives and Significance
The present study shows that TLR-4 plays a significant role in the regulation of arterial thrombosis. We demonstrated that LPS enhances arterial thrombosis formation in carotid artery injury by a TLR-4-dependent mechanism. Interestingly, we found that TLR-4 contributes to TF expression and activity in the injured vascular wall and causes increased TF activity in cultured ECs. Furthermore, we found that platelet-derived TLR-4 has no effect on the arterial thrombosis in a platelet depletion/reinfusion mouse model. These results provide evidence showing that TLR-4 positively regulates TF expression and activity in murine ECs and could, in part, explain how TLR-4 contributes to arterial thrombosis. Future studies are warranted to define a potential contribution of these mechanisms to the in vivo effects of TLR-4 on arterial thrombosis under pathological conditions such as atherosclerosis.
